Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy
Parent Company Invests Another $270m In Biocon Biologics After Earlier Allotment
Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.
